Just weeks after IntraBio secured a label expansion for its lead asset Aqneursa, Japanese drugmaker Shionogi is moving in to take the reins. Shionogi is handing over $2 billion for the Austin, Texas-based commercial biotech, in a deal that—in addition to Aqneursa—will grant access to IntraBio’s rare disease expertise and pipeline. The acquisition builds on Shionogi’s plans to diversify beyond its anti-infectious disease drug base and to beef up its budding rare disease unit, which was founded

Oct. 19, 2026 -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that its partner, the University of Oklahoma (OU), has received $2.9 million in funding from the National Cancer Institute (NCI) to study, in clinical trials, whether RedHill's opaganib[1], given after CAR (chimeric antigen receptor) T-cell therapy, may help immune cells fight cancer more effectively. The five-year, $2.9 million grant from the NCI is planne

TREMFYA maintained combined fistula remission through Week 48 across both maintenance dose regimens, including an increase from 28% at Week 24 to 35% at Week 48 in the 100 mg dose group These findings build on the Phase 3 clinical program, demonstrating efficacy in a dedicated, randomized, placebo-controlled trial in patients with this debilitating and challenging manifestation of Crohn's disease Oct. 19, 2026 -- Johnson & Johnson (NYSE: JNJ) today announced one-year results from the Phase 3 FU

Financing co-led by new investors Bain Capital Life Sciences, Forbion and Novo Holdings, with strong participation from additional new and existing investors Proceeds to advance MC2 receptor antagonist OMS1620 through Phase 2 development and generate early clinical data for SLC15A4 inhibitor 15 October 2026 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company developing small molecule therapeutics against highly validated target ecosystems, today announced an oversubscribed

Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinica

New designation expands on first Fast Track Designation in TMB-H colorectal cancer and is supported by monotherapy responses across multiple tumor types in the STARt-001 study Invikafusp alfa believed to be first immuno-oncology T-cell agonist to receive Fast Track Designation in a biomarker-defined, tissue-agnostic indication New designation supported by updated Phase 2 data in this population, which will be featured in an oral presentation at the European Society for Medical Oncology (ESMO) Co

RESEARCH TRIANGLE PARK, N.C., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Eclipse Life Sciences, Inc. , a privately held clinical-stage biopharmaceutical company developing next-generation therapies for retinal diseases, today announced positive topline results from its BETTIS-1 Phase 2 clinical trial comparing EC-104 fluocinolone acetonide (FA) extended release versus Ozurdex® for the treatment of diabetic macular edema (DME). EC-104 is a novel, completely biodegradable intravitreal corticosteroid imp

The Gilead Sciences deal, which include $135 million in upfront and near-term payments, marks a critical platform validation for Vir Biotechnology as investors await an upcoming readout in solid tumors. Gilead Sciences has helped bolster the appeal of Vir Biotechnology’s T cell engager technology with a new licensing deal that includes $135 million in upfront and near-term payments—including an equity stake—and could tack on an additional $1.74 billion in milestones. The upfront payment includ

Alaunos Therapeutics has bought Velaris Therapeutics, adding four biologics candidates discovered by Paragon Labs targeting pulmonary arterial hypertension (PAH) and related cardiopulmonary diseases. The transaction coincides with Paragon building out its own leadership bench with former executives from Apogee Therapeutics, another company — recently acquired by AbbVie for $10.9 billion — that had been built around Paragon-discovered assets. The Velaris buyout was accompanied by an oversubscribe

Medincell (Euronext Paris: MEDCL) today announced that it has secured an additional €13.8 million in non-dilutive financing from leading European commercial banks and Bpifrance. This additional financing follows the €28 million in non-dilutive bank financing announced in July 2026, bringing the total amount of non-dilutive financing secured since July 2026 to €41.8 million. The financing has been secured on market terms and does not include any equity-linked instruments, resulting in no dilutio